The
combination of photothermal therapy (PTT) and photodynamic
therapy (PDT) based on temperature increase and the formation of reactive
oxygen species (ROS), respectively, is an exciting avenue to provide
local and improved therapy of tumors with minimal off-site toxicity.
5-Aminolevulinic acid (ALA) is one of the most popular PDT pro-drugs,
and its efficiency improves significantly when delivered to tumors
with nanoparticles (NPs). But the tumor site’s hypoxic environment
is a handicap for the oxygen-consuming PDT process. In this work,
highly stable, small, theranostic NPs composed of Ag2S
quantum dots and MnO2, electrostatically loaded with ALA,
were developed for enhanced PDT/PTT combination of tumors. MnO2 catalyzes endogenous H2O2 to O2 conversion and glutathione depletion, enhancing ROS generation
and ALA-PDT efficiency. Ag2S quantum dots (AS QDs) conjugated
with bovine serum albumin (BSA) support MnO2 formation
and stabilization around Ag2S. AS-BSA-MnO2 provided
a strong intracellular near-infrared (NIR) signal and increased the
solution temperature by 15 °C upon laser irradiation at 808 nm
(215 mW, 10 mg/mL), proving the hybrid NP as an optically trackable,
long-wavelength PTT agent. In the in vitro studies, no significant
cytotoxicity was observed in the absence of laser irradiation in healthy
(C2C12) or breast cancer cell lines (SKBR3 and MDA-MB-231). The most
effective phototoxicity was observed when AS-BSA-MnO2-ALA-treated
cells were co-irradiated for 5 min with 640 nm (300 mW) and 808 nm
(700 mW) due to enhanced ALA-PDT combined with PTT. The viability
of cancer cells decreased to approximately 5–10% at 50 μg/mL
[Ag], corresponding to 1.6 mM [ALA], whereas at the same concentration,
individual PTT and PDT treatments decreased the viability to 55–35%,
respectively. The late apoptotic death of the treated cells was mostly
correlated with high ROS levels and lactate dehydrogenase. Overall,
these hybrid NPs overcome tumor hypoxia, deliver ALA to tumor cells,
and provide both NIR tracking and enhanced PDT + PTT combination therapy
upon short, low-dose co-irradiation at long wavelengths. These agents
that may be utilized for treating other cancer types are also highly
suitable for in vivo investigations.